Thompson Davis & CO. Inc. Takes $77,000 Position in biote Corp. (NASDAQ:BTMD)

Thompson Davis & CO. Inc. bought a new stake in biote Corp. (NASDAQ:BTMD) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 12,450 shares of the company’s stock, valued at approximately $77,000.

A number of other large investors have also added to or reduced their stakes in BTMD. SG Americas Securities LLC purchased a new position in biote during the fourth quarter valued at $76,000. MetLife Investment Management LLC grew its holdings in biote by 129.1% during the third quarter. MetLife Investment Management LLC now owns 16,582 shares of the company’s stock valued at $93,000 after purchasing an additional 9,343 shares during the period. Jane Street Group LLC grew its holdings in biote by 24.7% during the third quarter. Jane Street Group LLC now owns 16,873 shares of the company’s stock valued at $94,000 after purchasing an additional 3,342 shares during the period. Quarry LP bought a new stake in biote during the third quarter valued at about $104,000. Finally, Victory Capital Management Inc. bought a new stake in biote during the third quarter valued at about $106,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

biote Trading Down 6.1 %

NASDAQ:BTMD opened at $4.49 on Friday. The company has a market capitalization of $243.99 million, a P/E ratio of 17.27 and a beta of 1.04. biote Corp. has a 12 month low of $4.45 and a 12 month high of $8.44. The business’s 50-day moving average is $5.54 and its 200 day moving average is $5.75.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum assumed coverage on biote in a research note on Monday, December 16th. They issued a “buy” rating and a $12.00 price objective for the company.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.